Inovio Pharmaceuticals is developing DNA immune therapies to prevent and treat cancers and infectious diseases. Our SynCon immunotherapies delivered using our proprietary electroporation technology have generated best-in-class immune responses, with therapeutic T-cells exceeding other technologies. In a phase II cervical dysplasia study, our DNA immune therapy induced regression of precancerous…More cervical disease and cleared HPV infection. Roche exclusively licensed Inovio's DNA immunotherapies for prostate cancer and hepatitis B.
Social Media Links
REPORT RATINGS
4.8 / 5.0 (170)
Inovio Pharmaceuticals, Inc. reports have an aggregate usefulness score of 4.8 based on 170 reviews.